Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Jul 13;33(13-14):740–756. doi: 10.1089/hum.2021.255

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Francis Fonyuy Tukov et al. 2022; Published by Mary Ann Liebert, Inc.

This Open Access article is distributed under the terms of the Creative Commons License [CC-BY] (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Figure 5. — Neuroelectrophysiologic evaluations. (A) Sural (sensory) nerve conduction, (B) fibular/peroneal (sensory) nerve conduction, (C) saphenous (sensory) nerve conduction, and (D) tibial (motor) nerve conduction in males (M) and females (F) was determined at baseline, 2 weeks postdose (interim) and 13 weeks postdose (recovery) for NHPs in all four groups treated with onasemnogene abeparvovec. Group 1 was administered vehicle control item and contrast agent only. Group 2 was administered onasemnogene abeparvovec (3 × 10¹³ vg/animal) without immunosuppression. Group 3 was administered onasemnogene abeparvovec (3 × 10¹³ vg/animal) along with oral prednisolone (1 mg/kg). Group 4 was administered onasemnogene abeparvovec (3 × 10¹³ vg/animal) and a combination of intravenous rituximab and oral everolimus. NCV are all L (m/s). NCV, nerve conduction velocity.